

Viatriis in 2024

~1B

Patients Reached Annually¹

~1,400

Approved Molecules

>80B

Doses of Medicine Sold

>165

Countries & Territories Served

Access and Global Public Health

> Supplied more than 240 medicines on the WHO Essential Medicines List, representing nearly 50% of the total list

> Provided products that address the top 10 of the WHO’s leading causes of death globally

Our People

> Approximately 32,000 colleagues with industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise

> 100% of colleagues globally with access to wellbeing and mental health resources



Environment

> Achieved an ~19% reduction of our scope 1 and 2 GHG emissions through the end of 2024 compared to our 2020 base year

> Earned three British Standards Institute (BSI) Kitemark Certifications under the AMR Industry Alliance (AMRIA) Manufacturing Standard

Community

> Donated more than 174 million doses of medicines for humanitarian and emergency relief efforts through our partners around the world

> Continued our support of Rhiza Babuyile in South Africa to build three primary healthcare clinics

Financials

2024 Total Revenue: \$14.7 Billion

2024 Net Sales:

Brands

Generics

63%

37%

2024 Recognitions





Sources

¹The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2024 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viatriis Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viatriis medicines may be counted as multiple patients. Certain adjustments were applied to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.

1